Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

× No keyword cloud information.

11 in total

Review 1. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors: Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal: Future Oncol Date: 2015 Impact factor: 3.404

Review 2. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors: A Yacoub; O Odenike; S Verstovsek
Journal: Curr Hematol Malig Rep Date: 2014-12 Impact factor: 3.952

Review 3. Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.

Authors: Emily A Knight; Sylvia Osunsuyi-Fagbemi; Jessica Neely
Journal: J Adv Pract Oncol Date: 2015-11-01

Review 4. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.

Authors: Graeme Greenfield; Suzanne McPherson; Ken Mills; Mary Frances McMullin
Journal: J Transl Med Date: 2018-12-17 Impact factor: 5.531

5. Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system.

Authors: Vincenzo Accurso; Marco Santoro; Salvatrice Mancuso; Marisante Napolitano; Florinda Di Piazza; Antonio Russo; Sergio Mario Siragusa
Journal: Drugs Context Date: 2019-03-04

Review 6. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.

Authors: David M Ross; Jeffrey J Babon; Denis Tvorogov; Daniel Thomas
Journal: Haematologica Date: 2021-05-01 Impact factor: 9.941

Review 7. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.

Authors: Sime Brkic; Sara C Meyer
Journal: Hemasphere Date: 2020-12-29

Review 8. JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.

Authors: Michael Stephan Bader; Sara Christina Meyer
Journal: Pharmaceuticals (Basel) Date: 2022-01-28

Review 9. JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors: Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal: Front Cell Dev Biol Date: 2022-07-12

10. Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Authors: Maria-Theresa Krauth; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Felix Keil; Peter Krippl; Thomas Melchardt; Andreas Petzer; Holger Rumpold; Thamer Sliwa; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal: Wien Klin Wochenschr Date: 2018-07-24 Impact factor: 1.704